Alentis Therapeutics

Investment area

Venture Investments

Region

Europe

Date of investment

marts 2023

Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotechnology company that focuses on developing breakthrough treatments for CLDN1+ tumors and organ fibrosis.

Visit site

Contact

Naveed Siddiqi

Senior Partner

Department: Venture Investments

Naveed joined Novo Holdings A/S in 2019 and works from London and Copenhagen as a Senior Partner in Venture Investments.

He brings more than 25 years of experience in life science venture investments and investment banking.  Between 2013 and 2018, he was Partner at Andera Partners, a Paris based venture capital and growth equity firm with over 2 billion euros under management, focusing on life science investing.  He has also worked for Nomura Phase4 Ventures, Nomura International, EFG Corporate Finance, KPMG and as a medical doctor in the UK’s National Health Service.  During his career he has served on multiple European and US boards including at Novo Holdings with the Boards of Reviral (acquired by Pfizer), Vectivbio (IPO on NASDAQ), F2G Ltd, Amolyt SAS and Alentis Therapeutics. He is a Board Observer on the board of Numab AG.

Naveed obtained his medical degree from Guy’s and St Thomas’s Hospital Medical School (now King’s College London). Later, he also qualified as a chartered accountant from the Institute of Chartered Accountants England & Wales.